CTOs on the Move

VDDI Pharmaceuticals

www.virtualdrugdevelopment.com

 
VDDI Pharmaceuticals is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Qualyst

Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Olson Pharmacy Services

Olson Pharmacy Services is a Oregon City, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elixinol Global

The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.

Irix Pharmaceuticals

Irix Pharmaceuticals is a Florence, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cytovia Therapeutics

Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.